Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Myovant Sciences Ltd

Start price
Target price
Perf. (%)
€17.50
19.08.22
-
19.08.23
-4.00%
26.08.22

Could be very worthwhile Investment >20% year
buy
Cyclacel Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.29
18.08.22
€7.00
18.08.23
-33.11%
22.08.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Rising EBIT margin expected
EBIT growth >5% per year expected
buy
Crossject S.A.

Start price
Target price
Perf. (%)
€4.71
16.08.22
€5.00
16.08.23
-14.13%
12.11.22

Could be worthwhile Investment >10% per year
buy
ShockWave Medical Inc

Start price
Target price
Perf. (%)
€288.60
16.08.22
-
16.08.23
-29.14%
16.08.23

buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€106.80
16.08.22
-
16.08.23
-2.62%
16.08.23

buy
Rhythm Pharmaceuticals

Start price
Target price
Perf. (%)
€24.20
16.08.22
-
16.08.23
-4.96%
16.08.23

buy
PTC Therapeutics Inc.

Start price
Target price
Perf. (%)
€51.50
16.08.22
-
16.08.23
-27.77%
16.08.23

buy
Neurocrine Bioscience

Start price
Target price
Perf. (%)
€104.86
16.08.22
-
16.08.23
-6.73%
16.08.23

buy
BioMarin Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€94.03
16.08.22
-
16.08.23
-11.99%
16.08.23

buy
Seagen Inc.

Start price
Target price
Perf. (%)
€165.90
15.08.22
€180.00
31.01.24
9.64%
08.05.23

Could be very worthwhile Investment >20% year
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€2.91
13.08.22
€1.00
13.08.23
-12.70%
23.08.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Mediwound Ltd.

Start price
Target price
Perf. (%)
€1.97
13.08.22
€5.00
13.08.23
-6.09%
04.09.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Redhill Biopharma Ltd ADR

Start price
Target price
Perf. (%)
€1.06
13.08.22
€7.20
13.08.23
-13.55%
23.08.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Very low/no dividend yield expected
buy
Mediwound Ltd.

Start price
Target price
Perf. (%)
€1.97
13.08.22
€14.00
13.08.23
1.02%
22.08.22

Very Future proof/growth oriented business model
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
QIAGEN NV

Start price
Target price
Perf. (%)
€48.30
12.08.22
€55.00
12.08.23
-17.99%
13.08.23

Sanofi S.A.

Start price
Target price
Perf. (%)
€79.94
11.08.22
€63.00
30.09.24
26.47%
08.05.23

Could be worthwhile Investment >10% per year
buy
Sanofi S.A.

Start price
Target price
Perf. (%)
€79.36
11.08.22
€110.00
11.08.23
22.37%
12.08.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
buy
Global Blood Therapeutics Inc

Start price
Target price
Perf. (%)
€64.36
10.08.22
-
10.08.23
6.49%
10.08.23

buy
Dynavax Technologies Corp

Start price
Target price
Perf. (%)
€15.99
10.08.22
-
10.08.23
-18.71%
10.08.23

buy
Amicus Therapeutics Inc.

Start price
Target price
Perf. (%)
€12.10
10.08.22
-
10.08.23
3.34%
10.08.23

Novavax Inc.

Start price
Target price
Perf. (%)
€39.31
09.08.22
€30.00
09.08.23
-20.37%
09.09.22

buy
Valneva SE

Start price
Target price
Perf. (%)
€10.23
09.08.22
€14.00
09.08.23
-46.91%
30.05.23

Small cyclical dependencies
Below average Marketposition
Few uniques
buy
MorphoSys AG

Start price
Target price
Perf. (%)
€22.29
09.08.22
€28.00
09.08.23
24.14%
10.08.23

buy
Aphria Inc.

Start price
Target price
Perf. (%)
€12.71
08.08.22
-
08.08.26
-
11.03.24

Could be worthwhile Investment >10% per year
buy
Novo Nordisk A/S

Start price
Target price
Perf. (%)
€100.76
08.08.22
€120.00
08.08.23
69.31%
09.08.23